Tagged Articles

AbbVie 91 articles

AndroGel marketing ‘insidious,’ lawyers claim

AbbVie Inc.’s marketing of its testosterone replacement therapy AndroGel was part of an “insidious” plan to up its profits, argued attorneys for a man suing AbbVie over claims that the drug company didn’t study AndroGel’s cardiovascular risks. Jeffrey Konrad claims he used AndroGel for a few months before suffering a heart attack in 2010. He alleges that AbbVie was aware at that time that testosterone treatments were linked to cardiovascular risks, including heart attacks, strokes, and blood clots – all of which could be fatal. But AbbVie failed to adequately warn Konrad or his doctor of the risks so that ... Read More

AndroGel maker hit with $140M verdict in second bellwether trial

An Illinois federal jury slapped AbbVie Inc., with a $140 million verdict in the case of a man who sued the company alleging that it did not adequately test its testosterone treatment AndroGel to determine if it caused an increased cardiovascular risk and for misrepresenting the drug’s safety in treating an alleged off-label usage. The verdict was handed down 13 days after the trial began, with just under two days of deliberation. Plaintiff Jeffrey Konrad was awarded $140,000 in compensatory damages and $140 million in punitive damages. Konrad filed a lawsuit against AbbVie after suffering a heart attack while taking ... Read More

Testosterone replacement therapy seen in ‘negative shade of light’

The global market for testosterone replacement therapy is expected to reach a value of $1.3 billion by the end of 2024, according to market research group Transparency Market Research, a value lower than the previous year of $2 billion. As a result, the market will show a negative compounding annual growth rate of -4.2 percent over the course of the forecast period of 2016 to 2014, the report finds. This is despite a growing population of men who suffer from testosterone deficiency between the age of 40 to 79. Testosterone replacement therapy, such as AbbVie’s AndroGel, is used to treat ... Read More

Testosterone therapy market affected by health risks, legal issues

Testosterone replacement therapies enjoyed a boom in sales in recent years thanks to heavy advertising by drug companies like AbbVie Inc., which peddled its testosterone treatment AndroGel through television ads and websites aimed directly at male consumers. But the expansion of the testosterone market is slowing down thanks to stiffer prescribing requirements by the Food and Drug Administration (FDA). Sales may also be affected by high risk cardiovascular diseases, legal regulations and the risk of prostate cancer, according to WiseGuyReports’ latest analysis titled “The U.S. Testosterone Market Report: 2016 Edition.” Testosterone therapy has emerged as a prominent segment of the ... Read More

AbbVie, plaintiff say jury on their side

Both AbbVie Inc. and a man who sued the company over claims that its AndroGel testosterone treatment caused him to suffer a heart attack say the Illinois federal jury that handed the man a $150 million award was on their side, Law360 reports. The second testosterone side effects bellwether case to go to trial – and the first to be decided – concluded last month in a lawsuit brought by Jesse Mitchell and his wife. Mitchell says he was lured by AndroGel ads to ask his doctor about the testosterone treatment, which he took off and on for several years. Studies ... Read More

Testosterone makers fight proposed class action lawsuit

Endo Pharmaceuticals and its unit Auxilium Pharmaceuticals LLC filed a motion to compel compliance against UnitedHealthcare (UHC) in an Illinois federal court, arguing that the insurance company should hand over subpoenaed information about its dealings with testosterone replacement therapies if it wants to be part of a proposed class of insurers and third-party payors accusing testosterone manufacturers of fraudulently marketing the drugs. UHC isn’t a party in the litigation but is the largest member of the proposed class, making its information key to Endo and Auxilium, which are fighting against certification. But UHC has been avoiding calls, not returning messages, ... Read More

FDA considers first oral testosterone treatment

Two drug companies – both plagued by fits and starts– are racing to see which will be the first to gain Food and Drug Administration (FDA) approval for the first testosterone pill that can be taken by mouth. This week Lipocine announced it had resubmitted a New Drug Application (NDA) to the FDA for LPCN 1021, it’s oral testosterone replacement therapy designed to boost testosterone in men with low levels of the male hormone, a condition called hypogonadism. Lipocine had previously submitted an NDA to the FDA in June 2016 but was rejected. The agency cited problems with the dosing ... Read More

AndroGel verdict sends message to testosterone makers

AbbVie may have skirted claims that its testosterone replacement therapy AndroGel caused a man’s heart attack in the first trial to reach a verdict, but drug company was slapped with $150 million in punitive damages for misleading advertising, according to Law360. The jury’s action sends a strong signal to drug makers about deceptive direct-to-consumer advertising. Plaintiff Jesse Mitchell sued AbbVie, blaming his heart attack on AndroGel. His lawsuit cited studies that indicated testosterone treatments could increase the risk of heart attacks, strokes, blood clots and death. Mitchell also had other health problems that may have contributed to his injuries. But ... Read More

AbbVie hit with $150M punitive damages in testosterone trial

AbbVie Inc.’s AndroGel may not have caused Jesse Mitchell’s heart attack, but the company was sorely fraudulent in marketing its testosterone replacement therapy to Mitchell and other men for a made-up ailment, an Illinois federal jury found while laying out a $150 million verdict against the drug company, Law360 reported. Mitchell’s case was one of thousands in a multidistrict litigation (MDL) accusing manufacturers of testosterone treatments of not adequately warning that the hormone replacement therapy could cause heart attacks, strokes and blood clots, some of which can be fatal. The lawsuits also blame testosterone makers for creating a condition, called Low T, to ... Read More

Doctor testifies about testosterone heart risks

There is plenty of evidence to show that testosterone replacement therapy increases the risk for hear attacks, a cardiologist told an Illinois federal jury during the first trial among thousands in a multi district litigation alleging Abbie’s AndroGel causes heart risks, Law360 reports. Dr. Hossein Ardehali, a cardiologist at Northwestern University’s Feinberg School of Medicine, is an expert witness testifying for plaintiff Jesse Mitchell. Dr. Ardehali told jurors that he reviewed several studies involving men who took AndroGel and concluded that there was sufficient evidence to show the testosterone treatment increases cardiovascular risks. For example, he pointed to a 2010 ... Read More